Risk Factors for Bleeding and Thromboembolic Events in Patients With Chronic Kidney Disease on Maintenance Hemodialysis: A Retrospective Case‐Control Study Based on the Roxadustat User Population

Key Points

• This research aims to identify risk factors for bleeding and thromboembolic events in CKD patients undergoing hemodialysis, particularly focusing on roxadustat usage.
• Conducted a retrospective case-control study.
• Analyzed data from the roxadustat user population.
• Evaluated the incidence of bleeding and thromboembolic events.
• Roxadustat use was linked to a lower risk of both bleeding and thromboembolic events.
• Stabilization of hemoglobin levels was observed in patients on roxadustat.
• Improved iron metabolism and reduced inflammation were noted as possible mediating factors.